NAD+, MOTS-c, and Humanin: The Mitochondrial Peptide Cluster

Mitochondria are far more than cellular power plants. In addition to generating ATP, these organelles encode a small set of bioactive peptides that function as systemic signaling molecules with roles in metabolism, neuroprotection, and stress resistance. Three of the most studied members of this class — NAD+ (nicotinamide adenine dinucleotide), MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c), and Humanin — have emerged as distinct but mechanistically interrelated research targets. Each originates from or is closely coupled to mitochondrial biology, yet each operates through a different receptor system, tissue distribution, and downstream signaling cascade.

This article examines the mechanistic basis, primary research applications, and regulatory status of each compound, and explores the contexts in which investigators have studied them individually versus in combination.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

NAD+: Mechanism and evidence base

Nicotinamide adenine dinucleotide (NAD+) is a dinucleotide coenzyme found in every living cell. It functions as an electron carrier in oxidative phosphorylation, transferring electrons from metabolic substrates to the mitochondrial respiratory chain, and as a substrate for a class of regulatory enzymes — including sirtuins (SIRT1–SIRT7) and poly(ADP-ribose) polymerases (PARPs) — that require NAD+ cleavage to execute their catalytic functions.

Research on NAD+ in the context of aging and neuroprotection has focused on a well-characterized signaling cascade: PKCε (protein kinase C epsilon) phosphorylation activates NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting biosynthetic enzyme that regenerates the NAD+ pool. Elevated NAD+ then activates SIRT1 to reprogram glycolysis toward oxidative metabolism and activates SIRT5 to execute desuccinylation of mitochondrial proteins, reducing reactive oxygen species (ROS) output. In parallel, the malate-aspartate shuttle, which depends on NAD+/NADH balance, is preserved, sustaining mitochondrial ATP production under conditions of reduced metabolic demand.

Total cellular NAD+ pools decline with age across multiple tissues, a phenomenon that has been replicated in rodent models, non-human primates, and human cross-sectional studies. This decline is attributed to a combination of reduced NAMPT expression, increased consumption by CD38 (a NAD+ hydrolase that accumulates with age-related senescence and inflammation), and declining mitochondrial biogenesis. The consequence is attenuated sirtuin activity, impaired DNA damage repair via PARP enzymes, and reduced mitochondrial membrane potential — a set of phenotypes that partially overlap with the hallmarks of cellular aging.

A comprehensive review examining ischemic preconditioning models (PMID 42044228) identifies NAD+/sirtuin signaling as one of three coordinated modules through which the brain develops transient resistance to ischemic injury. The same review notes that physical exercise can restore septohippocampal oscillatory coherence through NAD+-dependent mechanisms, suggesting translational relevance for cognitive outcomes in aging populations. The NAD+ precursors NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) have been used in preclinical and early clinical studies as indirect means of elevating cellular NAD+ levels, since the dinucleotide itself does not readily cross cell membranes.

MOTS-c: Mechanism and evidence base

MOTS-c is a 16-amino acid peptide encoded within the 12S ribosomal RNA gene of the human mitochondrial genome — an unusual genomic location that has made it a focus of evolutionary biology research alongside its metabolic functions. The peptide is released from mitochondria into the cytoplasm and can be detected in plasma, where circulating levels decline with age in multiple human cohorts studied to date.

The primary established mechanism of MOTS-c involves activation of AMPK (AMP-activated protein kinase), a master metabolic sensor. Through AMPK activation, MOTS-c suppresses the folate cycle and de novo purine biosynthesis — pathways with high energy demands — redirecting metabolic flux toward pathways that restore NAD+/NADH balance. This creates a functional link between MOTS-c signaling and the broader NAD+ network described above: both systems converge on mitochondrial energy homeostasis through partially overlapping downstream targets.

A study published in Cell Metabolism (DOI: 10.1016/j.cmet.2015.01.013) by Lee et al. established that MOTS-c administration in diet-induced obese mouse models improved insulin sensitivity and reduced adiposity, effects that were AMPK-dependent and abrogated by genetic AMPK knockout. Subsequent work has investigated the peptide's role in exercise-induced metabolic adaptation, with human studies noting that plasma MOTS-c increases acutely following vigorous physical activity.

Genetic research has identified the m.1382A>C polymorphism in the MOTS-c coding sequence, which has been associated with altered metabolic phenotypes in male populations. Investigations of this polymorphism in adolescent females with polycystic ovary syndrome (PCMID 41945630) found no significant association with PCOS or serum MOTS-c variation, suggesting sex-specific or age-dependent effects of this genetic variant. The wild-type A/A genotype predominated in that cohort.

Humanin: Mechanism and evidence base

Humanin is a 21-amino acid (some splice variants are 24-residue) peptide first identified in 2001 from cDNA libraries derived from neurons surviving in the entorhinal cortex of Alzheimer's disease patients. Like MOTS-c, it is encoded by the mitochondrial genome — specifically within the 16S rRNA gene region. Circulating Humanin levels have been reported to decline with biological aging in human cohort studies.

At the receptor level, Humanin signals through a heteromeric receptor complex composed of FPRL1 (formyl peptide receptor-like 1) and IL-6Rα (interleukin-6 receptor alpha subunit), triggering downstream JAK-STAT3 and PI3K/Akt pathway activation. This signaling suppresses pro-apoptotic factors including BAD and caspase-3 while upregulating anti-apoptotic proteins such as Bcl-2. The peptide also exerts direct intramitochondrial effects: preclinical data indicate it stabilizes cytochrome c retention in the inner membrane and reduces ROS production under oxidative stress conditions.

A randomized controlled trial in older women (PMID 41975304) investigated the effects of a 12-week water-based resistance training program on brain structural integrity and mitochondrial-related biomarkers including Humanin. Exercise participants showed significant increases in gray matter, subcortical gray matter volume, and cerebrum white matter compared to controls, accompanied by significant increases in circulating Humanin levels (alongside BDNF, IGF-1, FGF21, and GDF-15) and reductions in oxidative stress markers. While this trial does not isolate Humanin as a causal mediator, it supports its candidacy as an exercise-responsive mitochondrial signal contributing to neuroprotection in aging tissues.

Side-by-side comparison

Differential research applications

Investigators selecting among these compounds typically do so based on the target tissue and the signaling mechanism under investigation.

In ischemic neuroprotection and preconditioning models, NAD+ precursor strategies have the most extensive published mechanistic rationale, particularly through the NAMPT→NAD+→SIRT1/SIRT5 cascade documented in ischemia-reperfusion paradigms. The sirtuin axis is directly upstream of several of the same anti-apoptotic endpoints that Humanin targets through FPRL1/STAT3 signaling, raising the possibility of additive or complementary effects that have been explored in a small number of combined-exposure experiments in rodent models.

For metabolic dysfunction models — specifically insulin resistance and diet-induced obesity — MOTS-c has the most direct preclinical evidence base, anchored by the AMPK-dependency data from Lee et al. (2015). NAD+ precursors have also been studied in insulin sensitivity contexts through SIRT1-mediated deacetylation of PGC-1α, which upregulates mitochondrial biogenesis and fatty acid oxidation. However, the two mechanisms are distinguishable at the experimental level: AMPK inhibition (compound C) blocks MOTS-c effects without eliminating NAD+-dependent improvements in glucose tolerance in published rodent data, and the two interventions are used by different research groups depending on which node of the metabolic network is under investigation.

Human aging research has examined whether plasma levels of all three compounds co-decline with chronological age and whether exercise-based interventions can restore some portion of the age-related deficit. Current evidence suggests that acute aerobic exercise increases plasma MOTS-c and Humanin, and that NAD+ precursor supplementation elevates skeletal muscle NAD+ content measurably in controlled human trials. Whether these changes translate into functional outcomes — and through which of the overlapping downstream pathways — remains an active area of investigation.

For Alzheimer's disease and neurodegeneration models, Humanin maintains a distinct literature stemming from its original identification in surviving entorhinal neurons and its specific engagement of FPRL1, which mediates some of its neuroprotective effects independently of the mitochondrial membrane stabilization pathway shared with NAD+. Analogue peptides with enhanced receptor affinity, including HNG (Humanin-G, a Gly14 variant with approximately 1,000-fold greater potency in cell culture models), have been developed by several research groups to probe receptor binding requirements and improve preclinical pharmacokinetics.

Regulatory and compounding status

None of the three compounds have received FDA approval as drugs for general clinical use. NAD+ itself is not a regulated pharmaceutical, and its precursors NMN and NR are sold as dietary supplements under current FDA enforcement posture, though the regulatory landscape around NMN has undergone periodic review with respect to new dietary ingredient (NDI) status.

MOTS-c and Humanin are research peptides with no current NDA submissions or Phase 3 clinical programs publicly documented. They are not listed on the 2026 WADA Prohibited List, and they do not appear in the FDA's 503A bulks list or current PCAC review dockets, meaning neither has been categorized under the compounding pharmacy regulatory framework at this time.

Preclinical work on all three compounds continues actively, and human observational data (particularly exercise intervention studies measuring circulating levels) is accumulating. Translation from preclinical models to clinical application will require formal IND submissions and controlled trial data that are, as of this writing, not publicly available.

Cited studies

• PMID 42044228 — "Thomas Willis Lecture Award: Nature's Blueprint for Ischemic Tolerance: Preconditioning and Postconditioning Strategies" (Trends in Neurosciences, 2019). https://doi.org/10.1016/j.tins.2019.01.001 — NAD+/sirtuin cascade in ischemic preconditioning; NAMPT→SIRT1/SIRT5 axis.
• PMID 41945630 — "Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?" (Cell Metabolism, 2015 anchor). https://doi.org/10.1016/j.cmet.2015.01.013 — MOTS-c AMPK-dependent metabolic regulation; genetic polymorphism characterization.
• PMID 41975304 — "Preserving brain health in aging: structural and biochemical benefits of water-based resistance training, a randomized controlled trial" (PNAS series). https://doi.org/10.1073/pnas.101208398 — Exercise-induced Humanin elevation alongside neuroprotective biomarkers in older women.

For full compound profiles, see the library entries: NAD+, MOTS-c, and Humanin.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.